CLINICAL_TRIALS
trial_result
· 2016-01-20
Clinical Trial Update: A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma [Phase 2]
Summary
A Phase 2 trial evaluating ASONEP for unresectable and refractory renal cell carcinoma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Lpath, Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED